ACIU AC Immune: ערך חשבונאי למניה

Investment inflows into AC Immune (ACIU) are driven by alliances with global pharmaceutical leaders to develop Alzheimer's treatments, while the market value of 0.48 already prices in trial risks. Massive expenditures and patent complexities make this sector accessible only to financially stable players. The price chart, which assists in the asset's baseline valuation, reflects the dynamics of a company developing neuro-drugs with a reliable cold-chain transportation system for components.

Investors use this metric to assess the intrinsic value of the business, determining the residual equity per share after all liabilities are settled. The current value of 0.48 reflects the actual resource reserve of AC Immune, which, in the absence of revenue and amid high clinical trial risks for Alzheimer's drugs, serves as the sole barrier against devaluation, as clearly demonstrated by the fair book value per share.